Greater Cannabis Company, Inc. (GCAN) — SEC Filings
Greater Cannabis Company, Inc. (GCAN) — 14 SEC filings. Latest: 10-Q (Nov 12, 2025). Includes 5 10-Q, 4 8-K, 2 10-K.
View Greater Cannabis Company, Inc. on SEC EDGAR
Overview
Greater Cannabis Company, Inc. (GCAN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Greater Cannabis Company, Inc. (GCAN) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $(669,369) compared to $(135,693) for the same period in 2024. This substantial increase was primarily driven by $(232,220) in loss on conversion of notes payable
Sentiment Summary
Across 14 filings, the sentiment breakdown is: 2 bearish, 12 neutral. The dominant filing sentiment for Greater Cannabis Company, Inc. is neutral.
Filing Type Overview
Greater Cannabis Company, Inc. (GCAN) has filed 5 10-Q, 4 8-K, 1 8-K/A, 1 10-Q/A, 1 10-K/A, 2 10-K with the SEC between Apr 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (14)
Risk Profile
Risk Assessment: Of GCAN's 14 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $(669,369) |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $21,355 |
| Operating Margin | N/A |
| Total Assets | $21,355 |
| Total Debt | $1,129,697 |
Key Executives
- Dr. Adi Aran, M.D.
- Elisha Kalfa
- Yonah Kalfa
- Fernando Bisker
Industry Context
The cannabinoid therapeutics industry is characterized by significant research and development, regulatory hurdles, and evolving market acceptance. Companies in this space often face long development cycles and require substantial funding to advance from preclinical to clinical stages. Competition is increasing as more players enter the market, driven by potential therapeutic applications.
Top Tags
financials (5) · 10-Q (4) · filing (3) · amendment (3) · cannabis (3) · Penny Stock (2) · corporate-events (2) · annual-report (2) · pharmaceuticals (2) · 10-K (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $669,369 | Increased from $135,693 in 2024 for the nine months ended September 30. |
| Total Revenue | $0 | No revenue generated for the nine months ended September 30, 2025 or 2024. |
| Note Default Penalties and Interest | $306,323 | New expense in 2025, contributing significantly to increased net loss. |
| Loss on Conversion of Notes Payable | $232,220 | New expense in 2025, contributing significantly to increased net loss. |
| Cash Balance | $21,355 | Decreased from $57,368 at December 31, 2024, indicating dwindling liquidity. |
| Accumulated Deficit | $5,329,714 | Increased from $4,660,345 at December 31, 2024, reflecting ongoing losses. |
| Common Shares Outstanding | 900,256 | As of September 30, 2025, up from 536,622 at December 31, 2024, indicating dilution. |
| Total Current Liabilities | $1,129,697 | Increased from $898,058 at December 31, 2024, highlighting growing debt burden. |
| SEC File Number | 000-56027 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 30-0842570 | Company's tax identification number. |
| Revenue | $0 | for the three months ended March 31, 2025, indicating no sales |
| Consulting Fees | $1,000 | for the three months ended March 31, 2025, paid to related parties |
| Reporting Period | Q1 2025 | Financials for the first quarter of 2025 are detailed. |
| Comparative Period | Q1 2024 | Financials for the first quarter of 2024 are used for comparison. |
| Fiscal Year End | 2024-12-31 | The period covered by the amended 10-K filing. |
Frequently Asked Questions
What are the latest SEC filings for Greater Cannabis Company, Inc. (GCAN)?
Greater Cannabis Company, Inc. has 14 recent SEC filings from Apr 2024 to Nov 2025, including 5 10-Q, 4 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GCAN filings?
Across 14 filings, the sentiment breakdown is: 2 bearish, 12 neutral. The dominant sentiment is neutral.
Where can I find Greater Cannabis Company, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Greater Cannabis Company, Inc. (GCAN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Greater Cannabis Company, Inc.?
Key financial highlights from Greater Cannabis Company, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for GCAN?
The investment thesis for GCAN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Greater Cannabis Company, Inc.?
Key executives identified across Greater Cannabis Company, Inc.'s filings include Dr. Adi Aran, M.D., Elisha Kalfa, Yonah Kalfa, Fernando Bisker.
What are the main risk factors for Greater Cannabis Company, Inc. stock?
Of GCAN's 14 assessed filings, 2 were flagged high-risk, 7 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Greater Cannabis Company, Inc.?
Forward guidance and predictions for Greater Cannabis Company, Inc. are extracted from SEC filings as they are enriched.